Corona Remedies Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Corona Remedies Ltd filed with BSE on 10 Aug 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
CORONA Remedies reported Q1 FY27 revenue growth of 21.9% year-on-year to Rs 422 crores, with EBITDA growing 33.5% and PAT growing 30.1%. Management said the India business grew 22.7%, outperforming the Indian Pharmaceutical Market's 11.6% growth, driven by a mix of volume, pricing and new product launches. The company also commercialized a new EU-GMP approved hormone manufacturing facility during the quarter and reaffirmed its FY27 revenue and profit growth targets.
Numbers mentioned
Revenue: INR422 crores (Q1 FY27)
p. 6
“revenue for Q1 FY27 stood at INR422 crores versus INR347 crores in Q1 FY26, reflecting a healthy growth of 21.9% Y-o-Y”
Bhavin Bhagat, page 6 of the filed PDF · View the filing
EBITDA: INR93 crores (Q1 FY27)
p. 6
“EBITDA stood at INR93 crores versus INR70 crores in Q1 FY26, a growth of 33.5% on a Y-o-Y basis”
Bhavin Bhagat, page 6 of the filed PDF · View the filing
EBITDA margin: 22% (Q1 FY27)
p. 6
“EBITDA margin improved by around 190 bps and stood at 22%”
Bhavin Bhagat, page 6 of the filed PDF · View the filing
Profit after tax: INR60 crores (Q1 FY27)
p. 6
“Profit after tax stood at INR60 crores compared to INR46 crores in Q1 FY26, a growth of 30.1% Y-o-Y”
Bhavin Bhagat, page 6 of the filed PDF · View the filing
PAT margin: 14.2% (Q1 FY27)
p. 6
“PAT margins for the quarter stood at 14.2% as compared to 13.3%, an increase of 90 bps on a year-on-year basis”
Bhavin Bhagat, page 6 of the filed PDF · View the filing
Revenue contribution from chronic segment: 73.4% (Q1 FY27)
p. 6
“Revenue contribution from chronic segment stood at 73.4% in Q1 FY27”
Bhavin Bhagat, page 6 of the filed PDF · View the filing
India business revenue growth: 22.7% (Q1 FY27)
p. 3
“Our India business delivered an impressive 22.7% year-on-year revenue growth in quarter 1 FY27, significantly outperforming the Indian Pharmaceutical Market, which grew by 11.6% during the same period”
Nirav Mehta, page 3 of the filed PDF · View the filing
Volume growth: 6.3% (MAT June 2026)
p. 4
“our volume growth stood 6.3%, significantly ahead of the IPM’s volume growth of 1.3%”
Nirav Mehta, page 4 of the filed PDF · View the filing
Price-led growth: 8.7% (MAT June 2026)
p. 4
“Our price-led growth was approximately 8.7% compared to 5.6% of the IPM as per MAT June PharmaTrac data”
Nirav Mehta, page 4 of the filed PDF · View the filing
Depreciation and amortization: INR13.4 crores (Q1 FY27)
p. 8
“the depreciation amortization was INR10 crores, which has increased to INR13.4 crores”
Bhavin Bhagat, page 8 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Revenue growth — 15% organic revenue growth · FY27
stated firmly by Nirav Mehta
p. 6
“We continue to target 15% revenue growth and 20% PAT growth over the FY27.”
Nirav Mehta, page 6 of the filed PDF · View the filing
PAT growth — 20% · FY27
stated firmly by Nirav Mehta
p. 8
“we continue to target 15% organic revenue growth and about 1.5% to 2% inorganic revenue growth resulted about 17% revenue growth and 20% PAT growth and we remain confident in our ability to achieve these objectives”
Nirav Mehta, page 8 of the filed PDF · View the filing
Inorganic revenue growth — 25% · FY27
stated firmly by Nirav Mehta
p. 13
“as far as FY27 is concerned, we have given a guidance of 25% growth out of inorganic and 15% revenue growth out of organic”
Nirav Mehta, page 13 of the filed PDF · View the filing
Medical representative additions — 200 to 250 medical representatives every year · FY27 and near-term future
stated firmly by Nirav Mehta
p. 10
“we will continue to remain about the guidance of 6% to 8% addition of medical representative, which is in the tune of 200 to 250 medical representative every year”
Nirav Mehta, page 10 of the filed PDF · View the filing
In-house manufacturing share — 60% in-house and 40% outsourced · FY27
stated firmly by Nirav Mehta
p. 12
“It is about 60-40, 60% in-house and 40% outsourced, and it will remain more or less 60-40 for FY27”
Nirav Mehta, page 12 of the filed PDF · View the filing
Hormonal facility asset turnover — turnover ratio of three
stated as an aspiration by Nirav Mehta
p. 10
“first year I think so the turnover ratio will be little less than one and then moving ahead, we will go to the turnover ratio of three”
Nirav Mehta, page 10 of the filed PDF · View the filing
Wokadine brand revenue — double from INR20 crores to INR40 crores · coming three years
stated firmly by Bhavin Bhagat
p. 9
“We have add a 25% growth for coming three years down the line to make the brand double in coming three years of INR20 crores to INR40 crores”
Bhavin Bhagat, page 9 of the filed PDF · View the filing
International business dossier filing — dossier ready · November-December 2026
stated conditionally by Nirav Mehta
p. 15
“I think so by November, December 2026, we will be ready with the dossier after completion of the bioequivalence, etc”
Nirav Mehta, page 15 of the filed PDF · View the filing
International business revenue kick-off — FY28-29
stated conditionally by Nirav Mehta
p. 16
“I think so we are projecting FY28-29 to, you know, kick-off this plant on an international level and we have high hope with international market also”
Nirav Mehta, page 16 of the filed PDF · View the filing
IPM industry growth — 9% to 11%
stated as an aspiration by Nirav Mehta
p. 7
“now it is sustainable, according to me this industry growth will continue to grow in the tune of around 10%, 9% to 11% in between”
Nirav Mehta, page 7 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management attributed the acceleration to normalization after COVID-era disruptions and expects sustainable growth going forward.
Answered by Nirav Mehta
Asked by Pratik Dharmshi: What is driving the acceleration in IPM growth since December?
p. 6
“industry has been anticipating the same thing that after Diwali, more or less around December 2026, everything will be normalized and IPM will come into the force of around double-digit -- lower double-digit growth and that exactly has been happened”
Nirav Mehta, page 6 of the filed PDF · View the filing
Management said margin performance depends on multiple factors and remained cautious about extrapolating current margins given cost volatility.
Answered by Nirav Mehta
Asked by Amey Chalke: Is there scope for margin improvement given strong growth or will incremental growth be reinvested?
p. 8
“we remain cautious about extrapolating the current margin profile into coming quarters given the evolving cost environment due to geopolitical Southeast Asia risk”
Nirav Mehta, page 8 of the filed PDF · View the filing
CFO confirmed depreciation would increase further due to the hormonal block going forward.
Answered by Amey Chalke
Asked by Amey Chalke: Will depreciation continue to rise due to the hormonal plant capitalization?
p. 9
“So, going ahead, we will expect the further increase on account of the hormonal block?”
Amey Chalke, page 9 of the filed PDF · View the filing
Management said the impact was limited in Q1 due to existing stock but flagged possible cost pressure ahead from geopolitical disruption.
Answered by Nirav Mehta
Asked by Alankar Garude: Did higher raw material prices impact Q1 and could this worsen in Q2?
p. 9
“the answer is yes, 100 basis point here and there we may get the hit and that's why we are trying to reduce other operating things and try to maintain the guidance which we have been told about 20% PAT growth”
Nirav Mehta, page 9 of the filed PDF · View the filing
Management said the first quarter was focused on supply chain integration and they remain confident of achieving the committed growth target in coming quarters.
Answered by Bhavin Bhagat
Asked by Alankar Garude: What is the status of Wokadine's growth trajectory versus the 25% target?
p. 10
“first quarter can't be considered for the future coming quarters numbers perspective, but we are eyeing what we have committed of our 25% growth of INR20 crores in Wokadine”
Bhavin Bhagat, page 10 of the filed PDF · View the filing
Management said they expect to maintain a top 10 position in the semaglutide market but their primary focus remains on other engine brands.
Answered by Nirav Mehta
Asked by Alankar Garude: How has the initial uptake been for the two semaglutide brands?
p. 10
“we should be maintain about top 10 position in the semaglutide market and we are expecting about INR1,500 crores to INR1,800 crores market and we will be well positioned over there”
Nirav Mehta, page 10 of the filed PDF · View the filing
CFO explained the higher costs stem from rapid medical representative hiring in recent years and expects operating leverage to bring costs down over time.
Answered by Bhavin Bhagat
Asked by Gopal Bhatt: Why are employee costs and other expenses higher than peers, and how will this be optimized?
p. 11
“almost 35% medical reps have been deployed in the last three years”
Bhavin Bhagat, page 11 of the filed PDF · View the filing
CFO clarified that pre-commercialization costs were capitalized as capex, and only post-commercialization costs will hit opex.
Answered by Bhavin Bhagat
Asked by Sidharth Negandhi: What costs related to the hormone facility are currently sitting in the P&L before commercialization?
p. 14
“whatever the cost which have been levied in the hormone plant before its commercialization are at capex level”
Bhavin Bhagat, page 14 of the filed PDF · View the filing
Management said the brand launched in June generated revenue roughly equal to the acquisition cost within the same quarter.
Answered by Nirav Mehta
Asked by Rahul Jeewani: How has the Bayer-Zydus acquired portfolio, specifically Noklot, performed?
p. 15
“we have given about INR7 crores as the, you know, acquisition cost and in the quarter, we have recovered INR7 crores out of it”
Nirav Mehta, page 15 of the filed PDF · View the filing
Management said approximately 60-65% of API consumption for hormonal products comes from La Chandra, with the rest sourced from other companies.
Answered by Nirav Mehta
Asked by Bhavika Singhvi: What is CORONA's captive API consumption from La Chandra Pharma Lab?
p. 17
“you can estimate about 60% to 65% API consumption from La Chandra and the others from the other part of the world, other companies of the API”
Nirav Mehta, page 17 of the filed PDF · View the filing
Risks flagged
Geopolitical disruption in Southeast Asia affecting input costs
p. 8
“we remain cautious about extrapolating the current margin profile into coming quarters given the evolving cost environment due to geopolitical Southeast Asia risk”
Nirav Mehta, page 8 of the filed PDF · View the filing
Raw material cost inflation from global geopolitical disturbance
p. 9
“The global geopolitical disturbance started around 27th, 28th of February and we already have about 70 to 90 days of stock”
Nirav Mehta, page 9 of the filed PDF · View the filing
Quarterly growth volatility due to product mix and seasonality
p. 12
“Quarterly growth can vary due to several factors including product mix, seasonality, and market dynamics”
Nirav Mehta, page 12 of the filed PDF · View the filing
Higher employee costs relative to peers due to lower productivity per medical representative
p. 11
“the employee cost would be high because the PCPM what they generate compared to the peers would be lower”
Bhavin Bhagat, page 11 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.